{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:31:44Z","timestamp":1792042304786,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1078985"],"award-info":[{"award-number":["1078985"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Sport and Health Science"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jshs.2020.11.009","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T12:07:55Z","timestamp":1606219675000},"page":"637-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["IGF1\u2013PI3K-induced\u00a0physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity"],"prefix":"10.1016","volume":"10","author":[{"given":"Sebastian","family":"Bass-Stringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.K.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jshs.2020.11.009_bib0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/physrev.00043.2016","article-title":"Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: Current knowledge and emerging concepts","volume":"98","author":"Bernardo","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jshs.2020.11.009_bib0002","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/01.CIR.0000048890.59383.8D","article-title":"Cardiology patient pages. Exercise and cardiovascular health","volume":"107","author":"Myers","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0003","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pcad.2014.10.001","article-title":"Exercise training in patients with heart disease: Review of beneficial effects and clinical recommendations","volume":"57","author":"Gielen","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jshs.2020.11.009_bib0004","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0140-6736(16)31743-3","article-title":"Global Burden of Disease Study 2015 provides GPS for global health 2030","volume":"388","author":"Reddy","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.jshs.2020.11.009_bib0005","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: A report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0006","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/01.CIR.0000081780.38477.FA","article-title":"Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: Results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial","volume":"108","author":"Giannuzzi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0007","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1161\/CIRCULATIONAHA.106.675041","article-title":"Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: A randomized study","volume":"115","author":"Wisl\u00f8ff","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0008","first-page":"15","article-title":"Cross country skiing and ski racing: A medical sports study. (Skilanglauf und Skidwettlauf. Eine medzinische Sporstudie)","volume":"2","author":"Henschen","year":"1899","journal-title":"Mit Med Klin Upsala"},{"key":"10.1016\/j.jshs.2020.11.009_bib0009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/01.CIR.101.3.336","article-title":"The athlete's heart. A meta-analysis of cardiac structure and function","volume":"101","author":"Pluim","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-2004-817827","article-title":"Left ventricular morphology and function in female athletes: A meta-analysis","volume":"25","author":"Whyte","year":"2004","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.jshs.2020.11.009_bib0011","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/01.CIR.61.4.832","article-title":"Echocardiographic evaluation of long-term effects of exercise on left ventricular hypertrophy and function in professional bicyclists","volume":"61","author":"Nishimura","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrm3495","article-title":"Molecular basis of physiological heart growth: Fundamental concepts and new players","volume":"14","author":"Maillet","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0013","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jshs.2020.11.009_bib0014","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1152\/physrev.00029.2014","article-title":"Are there deleterious cardiac effects of acute and chronic endurance exercise","volume":"96","author":"Eijsvogels","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jshs.2020.11.009_bib0015","doi-asserted-by":"crossref","first-page":"H1100","DOI":"10.1152\/ajpheart.00697.2019","article-title":"Guidelines for animal exercise and training protocols for cardiovascular studies","volume":"318","author":"Poole","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10409238.2013.857291","article-title":"Signaling pathways controlling skeletal muscle mass","volume":"49","author":"Egerman","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199728","article-title":"High-fat diet suppresses the positive effect of creatine supplementation on skeletal muscle function by reducing protein expression of IGF-PI3K-AKT-mTOR pathway","volume":"13","author":"Ferretti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jshs.2020.11.009_bib0018","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fnut.2019.00146","article-title":"The role of the IGF-1 signaling cascade in muscle protein synthesis and anabolic resistance in aging skeletal muscle","volume":"6","author":"Barclay","year":"2019","journal-title":"Front Nutr"},{"key":"10.1016\/j.jshs.2020.11.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107631","article-title":"Hypoactivity affects IGF-1 level and PI3K\/AKT signaling pathway in cerebral structures implied in motor control","volume":"9","author":"Mysoet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jshs.2020.11.009_bib0020","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.18632\/aging.103046","article-title":"Swimming exercise stimulates IGF1\/PI3K\/Akt and AMPK\/SIRT1\/PGC1alpha survival signaling to suppress apoptosis and inflammation in aging hippocampus","volume":"12","author":"Lin","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jshs.2020.11.009_bib0021","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/hh2301.100982","article-title":"Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes","volume":"89","author":"Neri Serneri","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jshs.2020.11.009_bib0022","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tem.2013.12.002","article-title":"New insights into IGF-1 signaling in the heart","volume":"25","author":"Troncoso","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jshs.2020.11.009_bib0023","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1210\/me.2008-0265","article-title":"Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy","volume":"22","author":"Kim","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0024","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1074\/jbc.M310405200","article-title":"The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110\u03b1) pathway","volume":"279","author":"McMullen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jshs.2020.11.009_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-10-4304-8_12","article-title":"The IGF1-PI3K-Akt signaling pathway in mediating exercise-induced cardiac hypertrophy and protection","volume":"1000","author":"Weeks","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0026","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jshs.2020.11.009_bib0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tcb.2019.01.001","article-title":"Class II PI3K functions in cell biology and disease","volume":"29","author":"Gulluni","year":"2019","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0028","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1194\/jlr.R089490","article-title":"VPS34 complexes from a structural perspective","volume":"60","author":"Ohashi","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jshs.2020.11.009_bib0029","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1242\/jcs.093773","article-title":"Classes of phosphoinositide 3-kinases at a glance","volume":"127","author":"Jean","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jshs.2020.11.009_bib0030","first-page":"1667","article-title":"Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110\u03b4","volume":"63","author":"Sawyer","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jshs.2020.11.009_bib0031","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fphar.2015.00169","article-title":"Phosphoinositide 3-kinase: Friend and foe in cardiovascular disease","volume":"6","author":"Ghigo","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0032","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1002\/j.1460-2075.1996.tb01049.x","article-title":"The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth","volume":"15","author":"Leevers","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.jshs.2020.11.009_bib0033","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0960-9822(99)80450-3","article-title":"Regulation of imaginal disc cell size, cell number and organ size by Drosophila class I(A) phosphoinositide 3-kinase and its adaptor","volume":"9","author":"Weinkove","year":"1999","journal-title":"Curr Biol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0034","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1093\/emboj\/19.11.2537","article-title":"The conserved phosphoinositide 3-kinase pathway determines heart size in mice","volume":"19","author":"Shioi","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.jshs.2020.11.009_bib0035","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1073\/pnas.1934654100","article-title":"Phosphoinositide 3-kinase (p110\u03b1) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy","volume":"100","author":"McMullen","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jshs.2020.11.009_bib0036","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase (p110\u03b1) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"McMullen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jshs.2020.11.009_bib0037","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0038","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/ATVBAHA.109.201988","article-title":"PI3K (p110 \u03b1) protects against myocardial infarction-induced heart failure: Identification of PI3K-regulated miRNA and mRNA","volume":"30","author":"Lin","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0039","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00125-012-2720-0","article-title":"Enhanced phosphoinositide 3-kinase(p110\u03b1) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes","volume":"55","author":"Ritchie","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jshs.2020.11.009_bib0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ Heart fail"},{"key":"10.1016\/j.jshs.2020.11.009_bib0041","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jshs.2020.11.009_bib0042","first-page":"2172","article-title":"The total artificial heart","volume":"7","author":"Cook","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jshs.2020.11.009_bib0043","article-title":"The patient with cardiovascular disease: Treatment strategies for preventing major events","volume":"29","author":"Cuffe","year":"2006","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0044","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jshs.2020.11.009_bib0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jshs.2020.11.009_bib0046","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.hlc.2018.03.005","article-title":"Adeno-associated virus gene therapy: Translational progress and future prospects in the treatment of heart failure","volume":"27","author":"Bass-Stringer","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jshs.2020.11.009_bib0047","unstructured":"Clinical Trials US National Library of Medicine. Investigation of the Safety and Feasibility of AAV1\/SERCA2a Gene Transfer in Patients With Chronic Heart Failure (SERCA-LVAD). ClinicalTrials.gov Identifier: NCT00534703. First posted: September 26, 2007."},{"key":"10.1016\/j.jshs.2020.11.009_bib0048","unstructured":"Clinical Trials US National Library of Medicine. AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure (AGENTHF). ClinicalTrials.gov Identifier: NCT01966887. First posted: October 22, 2013."},{"key":"10.1016\/j.jshs.2020.11.009_bib0049","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.jshs.2020.11.009_bib0050","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jshs.2020.11.009_bib0051","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Patients with Cardiac Disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jshs.2020.11.009_bib0052","doi-asserted-by":"crossref","first-page":"175fs8","DOI":"10.1126\/scitranslmed.3005798","article-title":"Seeing the light","volume":"5","author":"Wojno","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jshs.2020.11.009_bib0053","doi-asserted-by":"crossref","first-page":"H840","DOI":"10.1152\/ajpheart.00632.2019","article-title":"Gene therapy targeting cardiac phosphoinositide 3-kinase (p110\u03b1) attenuates cardiac remodeling in type 2 diabetes","volume":"318","author":"Prakoso","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0054","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","article-title":"Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy","volume":"6","author":"Okkenhaug","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jshs.2020.11.009_bib0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: Lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jshs.2020.11.009_bib0056","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jshs.2020.11.009_bib0057","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1752-8062.2010.00190.x","article-title":"Comparative cardiac gene delivery of adeno-associated virus serotypes 1\u22129 reveals that AAV6 mediates the most efficient transduction in mouse heart","volume":"3","author":"Zincarelli","year":"2010","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jshs.2020.11.009_bib0058","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.gt.3302895","article-title":"Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo","volume":"14","author":"Palomeque","year":"2007","journal-title":"Gene Ther"},{"key":"10.1016\/j.jshs.2020.11.009_bib0059","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nbt1073","article-title":"Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart","volume":"23","author":"Wang","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0060","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2011.042","article-title":"Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques","volume":"22","author":"Gao","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jshs.2020.11.009_bib0061","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/hum.2008.123","article-title":"Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat","volume":"19","author":"Bish","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jshs.2020.11.009_bib0062","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/gt.2010.105","article-title":"Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution","volume":"18","author":"Prasad","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.jshs.2020.11.009_bib0063","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biotechadv.2007.09.001","article-title":"Critical assessment of current adeno-associated viral vector production and quantification methods","volume":"26","author":"Aucoin","year":"2008","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.jshs.2020.11.009_bib0064","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1093\/hmg\/ddr141","article-title":"Large-scale recombinant adeno-associated virus production","volume":"20","author":"Kotin","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jshs.2020.11.009_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","article-title":"Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance","volume":"2","author":"Denduluri","year":"2015","journal-title":"Genes Dis"},{"key":"10.1016\/j.jshs.2020.11.009_bib0066","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1016\/j.febslet.2005.06.047","article-title":"HER2 signaling downregulation by trastuzumab and suppression of the PI3K\/Akt pathway: An unexpected effect on TRAIL-induced apoptosis","volume":"579","author":"Dubsk\u00e1","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jshs.2020.11.009_bib0067","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A \u201cdual-hit\u201d","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0068","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jshs.2020.11.009_bib0069","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib Ther"},{"key":"10.1016\/j.jshs.2020.11.009_bib0070","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/ERC-09-0140","article-title":"The clusterin paradigm in prostate and breast carcinogenesis","volume":"17","author":"Rizzi","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jshs.2020.11.009_bib0071","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-230X(09)05004-0","article-title":"Clusterin (CLU) and lung cancer","volume":"105","author":"Panico","year":"2009","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.jshs.2020.11.009_bib0072","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00204-020-02709-2","article-title":"Clusterin is regulated by IGF1-PI3K signaling in the heart: Implications for biomarker and drug target discovery, and cardiotoxicity","volume":"94","author":"Bass-Stringer","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jshs.2020.11.009_bib0073","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jshs.2020.11.009_bib0074","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2012.067","article-title":"Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL","volume":"4","author":"Efremov","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jshs.2020.11.009_bib0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/CS20171269","article-title":"Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling","volume":"132","author":"Bernardo","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jshs.2020.11.009_bib0076","doi-asserted-by":"crossref","first-page":"17615","DOI":"10.1073\/pnas.1206432109","article-title":"Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function","volume":"109","author":"Bernardo","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jshs.2020.11.009_bib0077","doi-asserted-by":"crossref","first-page":"22442","DOI":"10.1038\/srep22442","article-title":"Inhibition of miR-154 protects against cardiac dysfunction and fibrosis in a mouse model of pressure overload","volume":"6","author":"Bernardo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jshs.2020.11.009_bib0078","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1096\/fj.14-253856","article-title":"Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy","volume":"28","author":"Bernardo","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.jshs.2020.11.009_bib0079","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbalip.2017.12.003","article-title":"Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies","volume":"1863","author":"Tham","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jshs.2020.11.009_bib0080","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.celrep.2018.08.017","article-title":"Lipidomic profiles of the heart and circulation in response to exercise versus cardiac pathology: A resource of potential biomarkers and drug targets","volume":"24","author":"Tham","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jshs.2020.11.009_bib0081","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1038\/ncomms6705","article-title":"The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice","volume":"5","author":"Sapra","year":"2014","journal-title":"Nat Commun"}],"container-title":["Journal of Sport and Health Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095254620301605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095254620301605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:40:25Z","timestamp":1761860425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095254620301605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2095254620301605"],"URL":"https:\/\/doi.org\/10.1016\/j.jshs.2020.11.009","relation":{},"ISSN":["2095-2546"],"issn-type":[{"value":"2095-2546","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IGF1\u2013PI3K-induced\u00a0physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Sport and Health Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jshs.2020.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of Shanghai University of Sport.","name":"copyright","label":"Copyright"}]}}